Evolence, a collagen-based injectable filler, received FDA approval in 2008. It was approved for use in treating medium to deep lines and wrinkles in the face. Nasolabial folds respond particularly well to Evolence treatment.
Initial FDA Approval
Evolence was introduced in Europe in 2004. In 2005, the UK also approved the filler. In spite of growing use and positive results in European patients, the United States took longer to approve the product due to FDA regulations that require extensive testing.
Unlike many dermal fillers that are based on hyaluronic acid, Evolence is a collagen-based filler. The collagen is naturally derived and purified from porcine tendon material. It produces not only a filler effect, but also helps increase the structural foundation of the skin. Because of its naturally derived origins, patients are not required to undergo allergy testing before use.
Additional FDA Approvals
In 2009, the FDA approved Evolence to state that it is effective for as long as twelve months. It is the only dermal filler approved to make this claim, making it officially the longest lasting filler on the market. Long-term studies have proven it to be safe and effective, and many patients throughout Europe and the US have been treated with Evolence since its approval in 2008.